Ann: 2021 AGM Chairman's Address and CEO Presentation, page-62

Thanks Hottod, you are a goldmine of quality data points - current and historical

I guess we are still early, but how does PYC (pre-Clinical) discovery process/data points compare?

Been impressed by the process/data for VP-001 superior at that time, but have noticed industry catching up to soon making it the norm.

I share fellow HC’s bias to market not appreciating quantitative of PYC pre-clinical methodology hence making our beloved company seriously undervalued.

If PYC can somehow demonstrate capabilities to replicate our VP-001 discovery process to deliver multiple lead candidates across indications/modalities (as per AGM preso) then I guess the market (and industry) will make PYC more desirable.

Today we rest on VP-001 being our singular arrow, by end of ‘22 we should have a quiver full of them, with targets beyond rare ocular IRD indications…. I never quite liked statins:

https://www.forbes.com/sites/johnlamattina/2022/01/03/it-was-to-be-the-cholesterol-drug-for-the-masses-novartis-changed-that